KITE Kite Pharma, Inc.

-1.80  -2%
Previous Close 74.91
Open 74.80
Price To book 5.42
Market Cap 4.13B
Shares 56,545,000
Volume 1,183,307
Short Ratio 3.79
Av. Daily Volume 1,801,780

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 initiated October 2016. Phase 1 data due 2017.
KTE-C19 (ZUMA-6)
Refractory diffuse large B-cell lymphoma (DLBCL)
Phase 2 pivotal initiated November 2015. Data due 2018.
KTE-C19 (ZUMA-2)
Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) - cancer
Phase 2 data due 2018.
KTE-C19 (ZUMA-3)
Adult patients with r/r ALL - cancer
Phase 2 data due 2018.
KTE-C19 (ZUMA-4)
Pediatric and young adult patients with r/r ALL - cancer
PDUFA date under priority review November 29, 2017.
Axicabtagene ciloleucel (KTE-C19) - ZUMA-1
Refractory Non-Hodgkin's Lymphoma (NHL) - cancer

Latest News

  1. Kite Receives U.S. Food and Drug Administration Priority Review for Axicabtagene Ciloleucel
  2. I Still Can't Believe Juno Therapeutics Spent $46.4 Million on This Failed Drug
  3. Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting
  4. Kite Announces Presentations on Its Lead CAR-T Therapy Development Program at the 2017 American Society of Clinical Oncology Annual Meeting
  5. Newman Ferrara LLP Announces Corporate Governance Investigation of Kite Pharma Inc.
  6. This Hedge Fund’s Picks Returned 52% in Q1 And You’ve Never Heard of It
  7. Insider Buying Soars as Q1 Earnings Wind Up: Tempur Sealy, Apollo Global, Revlon, Kite Pharma and More
  8. Edited Transcript of KITE earnings conference call or presentation 8-May-17 12:30pm GMT
  9. Kite Pharma, Inc. – Value Analysis (NASDAQ:KITE) : May 11, 2017
  10. Insiders Are Loading Up on Kite Pharma, Cliffs Natural Resources and More
  11. Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death
  12. CYRX: Biopharma, Clinical Trial Growth, Fuels Another Record Quarter
  13. Kite Pharma, Inc. breached its 50 day moving average in a Bearish Manner : KITE-US : May 9, 2017
  14. Today's Research Reports on Trending Tickers: Celgene and Kite Pharma
  15. Kite Pharma (KITE) Posts Q1 Loss, Reveals CAR-T Patient Death
  16. SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Kite Pharma, Inc.
  17. KITE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Kite Pharma, Inc. To Contact The Firm
  18. These Drugmakers Plunged On Consensus-Lagging Q1 Sales, Losses
  19. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Kite Pharma, Inc.
  20. KITE Plunges, Take Sector With It